In building upon successful antitumor activity in the phase 1 trial, an additional phase 3 trial PAPILLION (NCT04538664) evaluated amivantamab plus chemotherapy versus standard chemotherapy alone as a first-line treatment for advanced NSCLC with EGFR Exon20ins mutation [32]. Here, EGFR is linked to non-small cell lung carcinoma.